Review of NICE Technology Appraisal Guidance No.156; Pregnancy - routine anti-D prophylaxis for rhesus negative women (review of TA41)

TA156; Pregnancy - routine anti-D prophylaxis for rhesus negative women (review of TA41) was published in August 2008.  

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal. 

No new evidence has become available that is relevant to the effectiveness and cost effectiveness of RAADP. There is some new research on topics associated with the technology, notably the use of noninvasive fetal blood-group determination, but this would not alter the recommendations of TA156.  Therefore, we recommend that the original guidance be transferred to the ‘static list’.

Topics on the static list may be transferred back to the active list for further consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted.